EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

EFFECT OF LATANOPROST/TIMOLOL AND BRINZOLAMIDE/BRIMONIDINE ON QUALITY OF LIFE IN GLAUCOMA: A COMPARATIVE STUDY

Smriti Chawla*, Jyoti Kaushal, Sumit Sachdeva

ABSTRACT

Introduction: Glaucoma is a term used to describe group of diseases of the eye characterized by progressive and irreversible damage to the optic nerve. Glaucoma causes ocular discomfort, fatigue and visual disturbances that interfere with quality of life (QOL). This study was done to observe the effect on quality of life with latanoprost/timolol versus brinzolamide/brimonidine fixed dose combination (FDC) in primary open angle glaucoma patients. Material & Methods: A prospective, randomized, comparative clinical study was conducted on 50 patients and they were randomly divided in two groups of 25 each to receive either Latanoprost and Timolol FDC (0.005+0.5% w/v) ophthalmic solution once daily (Group A) or Brinzolamide and Brimonidine FDC (1% +0.15% w/v) ophthalmic solution thrice daily (Group B) intra-ocularly for 12 weeks. Quality of life assessment was done by Glaucoma quality of life (GQL-15) and Glaucoma symptom scale (GSS) questionnaire. Results: On intragroup analysis, at the end of 12 weeks in group A & B there was reduction in GQL-15 score by 38.07% and 31.24% respectively compared to their baseline values (p< 0.001). On intergroup analysis, better response was seen in group A. On intragroup analysis at the end of 12 weeks in group A & B there was increase in GSS score by 2.5% and 1.6% respectively compared to their baseline values but it was statistically significant only in Group A at the end of 12 weeks (p<0.05). Thus, better response was seen with group A on intergroup analysis. Conclusion: Latanoprost & timolol showed more improvement in quality of life than brinzolamide & brimonidine in both parameters.

Keywords: Quality of life, Latanoprost, Timolol, Brinzolamide, Brimonidine, Glaucoma quality of life, Glaucoma Symptom Scale Questionnaire.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 April 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: APRIL ISSUE PUBLISHED

    APRIL 2024 issue has been successfully launched on APRIL 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia